Analysts expect Moderna to report Q3 2026 revenue of approximately $890.25 million and a loss per share of $1.10, with the stock currently trading at $258.38 against a consensus analyst price target of $107.10.
Investors are primarily focused on the commercial performance of the company's seasonal respiratory franchise, particularly the revenue contribution from its COVID-19, RSV, and recently launched flu vaccines.
Despite a remarkable 650% year-to-date stock rally driven by optimism surrounding the intismeran personalized cancer vaccine pipeline, the company faces year-over-year revenue pressure as it transitions toward its long-term oncology pivot. Shareholders will also be scrutinizing management's ability to maintain its year-end cash guidance of $4.7 billion to $5.2 billion amid continued clinical investment.